GALAPAGOS NV/S (NASDAQ:GLPG) Reaches New 12-Month High at $217.34

GALAPAGOS NV/S (NASDAQ:GLPG)’s stock price reached a new 52-week high during trading on Wednesday . The stock traded as high as $217.34 and last traded at $217.20, with a volume of 7391 shares traded. The stock had previously closed at $211.73.

A number of analysts have recently weighed in on GLPG shares. Citigroup lowered GALAPAGOS NV/S from a “buy” rating to a “neutral” rating in a research report on Wednesday, December 18th. Morgan Stanley lowered GALAPAGOS NV/S from an “overweight” rating to an “equal” rating and lifted their target price for the company from $193.00 to $215.00 in a report on Tuesday, December 17th. JPMorgan Chase & Co. cut GALAPAGOS NV/S from an “overweight” rating to a “neutral” rating and set a $205.00 target price for the company. in a research note on Sunday, January 5th. Royal Bank of Canada upped their price target on GALAPAGOS NV/S from $152.00 to $158.00 and gave the stock a “sector perform” rating in a report on Friday, November 15th. Finally, Bank of America began coverage on GALAPAGOS NV/S in a report on Monday, December 2nd. They set a “neutral” rating and a $199.00 price target on the stock. Ten investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $186.36.

The firm has a market capitalization of $11.83 billion, a price-to-earnings ratio of -330.64 and a beta of 1.58. The stock’s fifty day moving average price is $207.52 and its two-hundred day moving average price is $176.11. The company has a current ratio of 8.95, a quick ratio of 8.95 and a debt-to-equity ratio of 0.01.

GALAPAGOS NV/S (NASDAQ:GLPG) last issued its earnings results on Thursday, October 24th. The biotechnology company reported $8.72 EPS for the quarter, topping analysts’ consensus estimates of ($1.41) by $10.13. The firm had revenue of $715.97 million during the quarter, compared to the consensus estimate of $52.26 million. GALAPAGOS NV/S had a net margin of 32.09% and a return on equity of 25.34%. Analysts anticipate that GALAPAGOS NV/S will post 7.03 earnings per share for the current fiscal year.

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Morgan Stanley raised its position in shares of GALAPAGOS NV/S by 1.7% during the 2nd quarter. Morgan Stanley now owns 65,837 shares of the biotechnology company’s stock worth $8,488,000 after acquiring an additional 1,111 shares in the last quarter. State Street Corp raised its holdings in GALAPAGOS NV/S by 95.9% during the third quarter. State Street Corp now owns 39,599 shares of the biotechnology company’s stock worth $6,045,000 after purchasing an additional 19,384 shares in the last quarter. Victory Capital Management Inc. raised its holdings in GALAPAGOS NV/S by 35.0% during the second quarter. Victory Capital Management Inc. now owns 32,826 shares of the biotechnology company’s stock worth $4,232,000 after purchasing an additional 8,510 shares in the last quarter. Bank of America Corp DE lifted its position in shares of GALAPAGOS NV/S by 220.6% during the 2nd quarter. Bank of America Corp DE now owns 25,511 shares of the biotechnology company’s stock worth $3,290,000 after buying an additional 17,554 shares during the last quarter. Finally, Putnam Investments LLC boosted its holdings in shares of GALAPAGOS NV/S by 4.3% in the 2nd quarter. Putnam Investments LLC now owns 24,513 shares of the biotechnology company’s stock valued at $3,161,000 after buying an additional 1,000 shares in the last quarter. 15.29% of the stock is owned by institutional investors.

About GALAPAGOS NV/S (NASDAQ:GLPG)

Galapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes novel medicines. Its clinical stage programs include filgotinib, which is in Phase III clinical trials for the treatment of rheumatoid arthritis and Crohn's disease, Phase 2/3 trials for ulcerative colitis, and Phase II trials for multiple additional indications; GLPG1690, an autotaxin inhibitor, which is in Phase III clinical trial for the treatment of idiopathic pulmonary fibrosis; GLPG1972 that completed Phase 1b clinical trial for the treatment of osteoarthritis; and MOR106, which is in Phase II trials for atopic dermatitis patients.

Further Reading: Why are gap-down stocks important?

Receive News & Ratings for GALAPAGOS NV/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GALAPAGOS NV/S and related companies with MarketBeat.com's FREE daily email newsletter.